LifeMD, Inc. LFMD
Medical/Nursing Services · data as of November 13, 2026
LifeMD, Inc. (LFMD) is a healthcare company listed in the US with a market value of about $106M. In the twelve months to September 30, 2026 it had revenue of $189M and net income of $400420, a net margin of 0.2%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 264.1, 5-year revenue growth of 39% a year, a 5-year average ROIC of -115%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.
About LifeMD
LifeMD is listed in the US and classified in medical/nursing services. Revenue went from $714158 in 2014 to $194M in 2025, growth of about 66.5% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 46% over three years (dilution for shareholders).
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Pays a dividend
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189M | $194M | $155M | $153M | $119M | $93M | $37M | $12M | $8M | $5M | $5M |
| Net income | $400420 | $14M | -$21M | -$21M | -$46M | -$61M | -$59M | -$3M | -$1M | -$1M | -$1M |
| Free cash flow | -$11M | $6M | $16M | $9M | -$23M | -$33M | — | — | — | — | — |
| EPS (diluted) | $0.01 | $0.25 | $-0.60 | $-0.70 | $-1.57 | $-2.29 | $-4.44 | $-0.32 | $-0.25 | $-0.15 | $-0.15 |
| Net margin | 0.2% | 7.4% | -13.8% | -13.5% | -38.2% | -65.6% | -157.3% | -25.2% | -14.9% | -24.1% | -21.1% |
| ROIC | — | -20.5% | -212.8% | -51.0% | — | -174.5% | — | — | -140.0% | -79.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $6.88, 213% above the current price; targets range from $3.00 to $9.00; the consensus rating is “Strong buy”; expected EPS is $-0.34 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is LifeMD’s P/E ratio?
About 264.1, based on the last twelve months of diluted earnings per share (forward P/E about 30.3).
Is LifeMD stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does LifeMD pay a dividend?
Not currently.
Is LifeMD a good stock to buy?
We do not give buy or sell advice. LifeMD scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.